Bafrekalant

• CAT Number: I045118
• CAS Number: 2256770-44-0
• Molecular Formula: C29H31ClN6O2
• Molecular Weight: 531.05
• Purity: ≥95%
• Synonyms: (3-chloro-6-methoxypyridin-2-yl)-[3-[[2-(4-propan-2-ylphenyl)imidazo[1,2-a]pyrimidin-3-yl]methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone
• IUPAC Name: (3-chloro-6-methoxypyridin-2-yl)-[(1S,5R)-3-[[2-(4-propan-2-ylphenyl)imidazo[1,2-a]pyrimidin-3-yl]methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone
• InChI: InChI=1S/C29H31ClN6O2/c1-18(2)19-5-7-20(8-6-19)26-24(35-14-4-13-31-29(35)33-26)17-34-15-21-9-10-22(16-34)36(21)28(37)27-23(30)11-12-25(32-27)38-3/h4-8,11-14,18,21-22H,9-10,15-17H2,1-3H3/t21-,22+
• InChIKey: VDKJCAWGDJJKNL-SZPZYZBQSA-N
• SMILES: CC(C)C1=CC=C(C=C1)C2=C(N3C=CC=NC3=N2)CN4C[C@H]5CC[C@@H](C4)N5C(=O)C6=C(C=CC(=N6)OC)Cl

Bafrekalant（Cat No.:I045118）is an investigational oral leukotriene B4 receptor 1 (BLT1) antagonist being developed for the treatment of chronic inflammatory and respiratory conditions, such as chronic obstructive pulmonary disease (COPD) and asthma. By blocking BLT1, Bafrekalant inhibits leukotriene B4–mediated neutrophil recruitment and activation, reducing airway inflammation and tissue damage. Its selective mechanism offers a novel approach distinct from corticosteroids and bronchodilators, with potential for improved safety and efficacy. Bafrekalant is supplied for research focused on leukotriene signaling, neutrophilic inflammation, and next-generation therapies for pulmonary and inflammatory diseases.